ClinConnect ClinConnect Logo
Search / Trial NCT05199857

WE BEAT - HEART Club Fontan Wellness Project: A Virtual Resilience Promotion and Frailty Prevention Program

Launched by UNIVERSITY OF MICHIGAN · Jan 7, 2022

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Wellness Education Exercise Program

ClinConnect Summary

The WE BEAT - HEART Club Fontan Wellness Project is a clinical trial designed to help young patients with a specific heart condition called Fontan physiology. This trial is looking at how a small-group wellness education program, along with personalized exercise plans, can improve the health and daily activities of these pediatric patients. The study will assess whether this program is safe and acceptable, and it aims to see if participants become less frail, improve their physical fitness, increase their daily activity levels, and report a better quality of life after completing the program.

To be eligible for the trial, participants must be between 13 and 19 years old, have Fontan physiology, and be able to use a mobile device for program activities. They should also have the consent of a parent or guardian. During the trial, participants will take part in both educational sessions and exercise programs over a period of time, and they will be monitored for progress and safety. Overall, this study hopes to promote better health and well-being for young people living with this heart condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Males and females with Fontan physiology who are 13 to \<19 years of age at enrollment
  • Own a mobile device capable of installing the University of Michigan Patient Portal application
  • Fluent in English
  • Participant consent or parental/guardian consent and participant assent
  • Exclusion Criteria:
  • Height \< 130 centimeters
  • Current intravenous inotropic drugs
  • Severe ventricular dysfunction assessed qualitatively by clinical echocardiography within six months prior to enrollment.
  • Severe valvar regurgitation, ventricular outflow obstruction, or aortic arch obstruction assessed by clinical echocardiography within six months prior to enrollment.
  • History of arrhythmia with exercise (excluding isolated supraventricular or ventricular ectopy without symptoms).
  • Inability to complete exercise testing at baseline screening.
  • Noncardiac medical, developmental, and/or social disorder that would prevent successful completion of planned study testing or would invalidate its results.
  • Suicidality or homicidality in the past 6 months.

About University Of Michigan

The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.

Locations

Ann Arbor, Michigan, United States

Ann Arbor, Michigan, United States

Patients applied

0 patients applied

Trial Officials

Jesse Hansen, MD

Principal Investigator

University of Michigan

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials